The startup develops a targeted molecular treatment for fragile X syndrome, a genetic condition leading to intellectual disabilities. This therapy aims to improve cognitive function and quality of life for individuals affected by rare neurodevelopmental syndromes.
Funding
$12.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Fragile X syndrome and KCNMA1-linked channelopathies are rare genetic disorders that can cause significant neurodevelopmental issues, including intellectual disability and central nervous system hyper-excitability. Current treatment options are limited and do not address the underlying ion channel dysfunction contributing to these conditions.
Solution
Kaerus Bioscience is developing targeted therapeutics that modulate BK (KCa1.1, Slo1, Maxi-K) channels to address the underlying ion channel dysfunction in Fragile X syndrome and other rare genetic syndromes linked to the KCNMA1 gene. Their small molecule modulators aim to correct central nervous system hyper-excitability associated with these conditions. By targeting the BK channels, Kaerus Bioscience seeks to provide novel treatments that can improve the lives of patients affected by these rare neurodevelopmental disorders. The lead program, KER-0193, is a BK channel modulator in preclinical development for Fragile X syndrome.
Target Audience
The primary target audience includes individuals affected by Fragile X syndrome and KCNMA1-linked channelopathies, as well as their families and caregivers.
Features
- Proprietary small molecule modulators of BK (KCa1.1, Slo1, Maxi-K) channels
- Targeted therapeutics addressing ion channel dysfunction in rare genetic syndromes
- Lead program KER-0193 in preclinical development for Fragile X syndrome
- Expanding focus to other rare genetic syndromes linked to the KCNMA1 gene